Guidelines for Therapeutic Management of Parkinson’s Disease in China

Lin Lu, Shengdi Chen, Yuting Yang, Yangfu Luo, Pingyi Xu, Weidong Le

Research output: Chapter in Book/Report/Conference proceedingChapter


Parkinson’s disease (PD) is the most common age-related neurodegenerative movement disorder, affecting around 1.7% of the population over 65 years old in China. The pathological feature of PD is the accumulation of a-synucleincontaining intraneuronal inclusions and progressive loss of dopaminergic neurons in midbrains. PD is clinically characterized by both motor and non-motor symptoms. In the past 20 years, Chinese researchers and clinicians have made significant progress in understanding the pathogenesis of PD, discovering biomarkers for early diagnosis, and developing novel therapeutic strategies to combat this disease. Until now, the Chinese Society of Parkinson’s Disease and Movement Disorders have published four editions of the Chinese Parkinson’s Disease Treatment Guidelines in 2006, 2009, 2014, and 2020. In this chapter, we will describe the main contents of these guidelines and summarize recent progress of PD treatment in China.

Original languageEnglish (US)
Title of host publicationNeuroPsychopharmacotherapy
PublisherSpringer International Publishing
Number of pages20
ISBN (Electronic)9783030620592
ISBN (Print)9783030620585
StatePublished - Jan 1 2022


  • China
  • Individualized therapeutics
  • Parkinson’s disease
  • Treatment guideline

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'Guidelines for Therapeutic Management of Parkinson’s Disease in China'. Together they form a unique fingerprint.

Cite this